KUALA LUMPUR, Feb 26 (Bernama) -- Curia, a contract research, development and manufacturing organisation (CDMO), has appointed Steve Lavezoli as vice president of biologics.
In a statement, the company said he will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.
“Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts.
“Under his guidance, I have every confidence that we will further our mission of life-changing life science,” said its chief executive officer, Philip Macnabb.
Meanwhile, Lavezoli said: “Curia holds a unique position in the CDMO industry with an impressive end-to-end offering.
“It is an honour to join a team with such deep scientific expertise and values-driven purpose to drive a positive impact on patients’ lives.”
Lavezoli most recently worked for Scorpius Biologics, a startup CDMO focused on microbial and mammalian biologics development and manufacturing as the vice president of commercial operations.
Prior to joining Scorpius, he spent four years with Catalent Biologics, focused on drug substance business development in the United States for early-stage clinical programmes and later focusing on late-stage commercial programme integration.
Lavezoli earned his Bachelor of Science in chemical engineering from Pennsylvania State University.
-- BERNAMA
No comments:
Post a Comment